Research ArticleArticle
Context-Dependent Antagonism between Akt Inhibitors and Topoisomerase Poisons
Marina Gálvez-Peralta, Karen S. Flatten, David A. Loegering, Kevin L. Peterson, Paula A. Schneider, Charles Erlichman and Scott H. Kaufmann
Molecular Pharmacology May 2014, 85 (5) 723-734; DOI: https://doi.org/10.1124/mol.113.088674
Marina Gálvez-Peralta
Divisions of Oncology Research (M.G.-P., K.S.F., D.A.L., K.L.P., P.A.S., S.H.K.) and Medical Oncology (C.E.), Department of Oncology and Department of Molecular Pharmacology & Experimental Therapeutics (S.H.K.), Mayo Clinic College of Medicine, Rochester, Minnesota
Karen S. Flatten
Divisions of Oncology Research (M.G.-P., K.S.F., D.A.L., K.L.P., P.A.S., S.H.K.) and Medical Oncology (C.E.), Department of Oncology and Department of Molecular Pharmacology & Experimental Therapeutics (S.H.K.), Mayo Clinic College of Medicine, Rochester, Minnesota
David A. Loegering
Divisions of Oncology Research (M.G.-P., K.S.F., D.A.L., K.L.P., P.A.S., S.H.K.) and Medical Oncology (C.E.), Department of Oncology and Department of Molecular Pharmacology & Experimental Therapeutics (S.H.K.), Mayo Clinic College of Medicine, Rochester, Minnesota
Kevin L. Peterson
Divisions of Oncology Research (M.G.-P., K.S.F., D.A.L., K.L.P., P.A.S., S.H.K.) and Medical Oncology (C.E.), Department of Oncology and Department of Molecular Pharmacology & Experimental Therapeutics (S.H.K.), Mayo Clinic College of Medicine, Rochester, Minnesota
Paula A. Schneider
Divisions of Oncology Research (M.G.-P., K.S.F., D.A.L., K.L.P., P.A.S., S.H.K.) and Medical Oncology (C.E.), Department of Oncology and Department of Molecular Pharmacology & Experimental Therapeutics (S.H.K.), Mayo Clinic College of Medicine, Rochester, Minnesota
Charles Erlichman
Divisions of Oncology Research (M.G.-P., K.S.F., D.A.L., K.L.P., P.A.S., S.H.K.) and Medical Oncology (C.E.), Department of Oncology and Department of Molecular Pharmacology & Experimental Therapeutics (S.H.K.), Mayo Clinic College of Medicine, Rochester, Minnesota
Scott H. Kaufmann
Divisions of Oncology Research (M.G.-P., K.S.F., D.A.L., K.L.P., P.A.S., S.H.K.) and Medical Oncology (C.E.), Department of Oncology and Department of Molecular Pharmacology & Experimental Therapeutics (S.H.K.), Mayo Clinic College of Medicine, Rochester, Minnesota
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Effect of Akt Inhibition on Action of Topoisomerase Poisons
Marina Gálvez-Peralta, Karen S. Flatten, David A. Loegering, Kevin L. Peterson, Paula A. Schneider, Charles Erlichman and Scott H. Kaufmann
Molecular Pharmacology May 1, 2014, 85 (5) 723-734; DOI: https://doi.org/10.1124/mol.113.088674
Research ArticleArticle
Effect of Akt Inhibition on Action of Topoisomerase Poisons
Marina Gálvez-Peralta, Karen S. Flatten, David A. Loegering, Kevin L. Peterson, Paula A. Schneider, Charles Erlichman and Scott H. Kaufmann
Molecular Pharmacology May 1, 2014, 85 (5) 723-734; DOI: https://doi.org/10.1124/mol.113.088674
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement